APA (7th ed.) Citation

Zhao, W., Wang, B., Chen, L., Fu, W., Xu, J., Liu, J., . . . He, A. (2022). Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: A phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). Journal of hematology and oncology, 15(1), 1-12. https://doi.org/10.1186/s13045-022-01301-8

Chicago Style (17th ed.) Citation

Zhao, Wan-Hong, et al. "Four-year Follow-up of LCAR-B38M in Relapsed or Refractory Multiple Myeloma: A Phase 1, Single-arm, Open-label, Multicenter Study in China (LEGEND-2)." Journal of Hematology and Oncology 15, no. 1 (2022): 1-12. https://doi.org/10.1186/s13045-022-01301-8.

MLA (9th ed.) Citation

Zhao, Wan-Hong, et al. "Four-year Follow-up of LCAR-B38M in Relapsed or Refractory Multiple Myeloma: A Phase 1, Single-arm, Open-label, Multicenter Study in China (LEGEND-2)." Journal of Hematology and Oncology, vol. 15, no. 1, 2022, pp. 1-12, https://doi.org/10.1186/s13045-022-01301-8.